PAPADOPOULOS STELIOS

Average Profitability
29.89%
Insider Buys Quantity
12
Insider Buys Sum
$8.92M
Insider Sells Quantity
13
Insider Sells Sum
$25.78M

Insider Activity of PAPADOPOULOS STELIOS

According to the SEC Form 4 filings, PAPADOPOULOS STELIOS, being in a position of

  1. director at Exelixis, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 11437 shares for $240,177,
    over all time since 2008-10-30, has bought 500000 shares for $1.58M, and sold 437972 shares for $10.83M.

The largest purchase of all time was on 2015-07-27 and amounted to 15000 shares of Biogen Inc. for $4.57M.

The largest sale of all time was on 2013-03-11 and amounted to 81675 shares of Biogen Inc. for $14.07M.

Biography of PAPADOPOULOS STELIOS

No biography is available at this moment.

2024-05-20SaleExelixis, Inc.
EXEL
director
11,437
0.0039%
$21.00$240,177+22.02%
2022-02-22SaleExelixis, Inc.
EXEL
director
84,515
0.0264%
$19.56$1.65M-8.62%
2021-05-11SaleExelixis, Inc.
EXEL
director
20,770
0.0067%
$24.98$518,794-20.62%
2020-05-08SaleExelixis, Inc.
EXEL
director
45,000
0.0145%
$25.84$1.16M-12.27%
2019-05-07PurchaseRegulus Therapeutics Inc.
RGLS
director
370,370
1.9953%
$1.08$400,000-40%
2019-02-21SaleExelixis, Inc.
EXEL
director
26,250
0.0087%
$21.25$557,813-6.83%
2018-12-28PurchaseRegulus Therapeutics Inc.
RGLS
director
50,000
0.569%
$1.09$54,570-12.73%
2018-12-27PurchaseRegulus Therapeutics Inc.
RGLS
director
26,401
0.2916%
$1.04$27,460-10.65%
2018-12-26PurchaseRegulus Therapeutics Inc.
RGLS
director
90,000
0.9471%
$0.95$85,878-6.73%
2018-11-16PurchaseRegulus Therapeutics Inc.
RGLS
director
300,000
3.3093%
$1.38$415,470-27.78%
2018-11-15PurchaseRegulus Therapeutics Inc.
RGLS
director
200,000
2.3033%
$1.33$265,080-21.21%
2018-05-07SaleExelixis, Inc.
EXEL
director
15,000
0.005%
$22.15$332,250-7.11%
2018-03-02SaleExelixis, Inc.
EXEL
director
15,000
0.0051%
$24.05$360,750-14.02%
2017-09-22SaleExelixis, Inc.
EXEL
director
10,000
0.0035%
$25.40$254,000-7.19%
2017-09-19SaleExelixis, Inc.
EXEL
director
127,790
0.043%
$27.63$3.53M-16.35%
2017-09-18SaleExelixis, Inc.
EXEL
director
72,210
0.0247%
$27.76$2M-14.88%
2017-07-25PurchaseRegulus Therapeutics Inc.
RGLS
director
1M
0.9102%
$0.91$910,000-17.12%
2017-03-22PurchaseRegulus Therapeutics Inc.
RGLS
director
300,000
0.5557%
$1.23$368,100-8.8%
2017-03-21PurchaseRegulus Therapeutics Inc.
RGLS
director
200,000
0.3771%
$1.20$239,800-4.17%
2017-03-20SaleExelixis, Inc.
EXEL
director
10,000
0.0034%
$21.66$216,600+18.19%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.